For policymakers & clinicians
Neutropenia has NCCN and ASCO/IDSA guidance and approved growth factors. A low absolute lymphocyte count is associated with poorer outcomes in many cancer studies, but association alone does not establish that raising the count improves survival. This page reviews the evidence, treatment-specific guidance and remaining research questions.
The evidence in brief
The association is old, consistent, and cuts across tumor type and treatment modality. In 802 patients with lymphoma, metastatic breast cancer and advanced sarcoma, baseline lymphopenia (<1,000/µL) was present in about a quarter and independently predicted shorter overall survival in all three (RR 1.46–1.8) (Ray-Coquard et al., Cancer Research 2009). In 1,051 patients starting chemotherapy, a day-1 lymphocyte count ≤700/µL was associated with early death (reported effect estimate 3.1; the paper labels it an HR despite using logistic regression) (Ray-Coquard et al., BJC 2001).
Treatment-induced lymphopenia is at least as important as baseline. In 297 patients with glioma, pancreatic and lung cancer, 83% began chemoradiation with a normal count; the median fell 63% by two months, 43% reached grade 3–4, and severe lymphopenia was associated with a higher hazard of death (HR 2.1, 95% CI 1.54–2.78). The median count stayed below 1,000 for the entire year (Grossman et al., JNCCN 2015). Deaths were overwhelmingly from tumor progression, not infection (Grossman et al., CCR 2011).
Meta-analyses agree: pooled adjusted HR 1.65 for severe radiation-induced lymphopenia across 20 studies, 1.92 in pancreas and 1.63 in brain (Damen 2021); HR 2.33 in a pancreas-specific analysis (Venkatesulu 2022); HR 1.99 in 1,944 glioma patients (2021 meta-analysis).
The immunotherapy era sharpened the point. In 10,498 propensity-matched patients starting checkpoint inhibitors, baseline ALC below 1.5 × 10⁹/L meant 24-month survival of 27.9% versus 35.3% (HR 1.26); the authors recommend incorporating baseline ALC into routine risk assessment (Ismail et al., Cancers 2026). In 18,186 real-world patients, higher baseline lymphocyte count was independently associated with better survival (Goldschmidt et al., 2023).
The gap
The practical consequence. Beth's family reports persistent low lymphocyte counts after chemotherapy ended in September 2023, with a documented value of 525 in January 2026. This does not mean her count was exactly 525 throughout that period. Her experience motivates the request to discuss persistent low counts with the treating team.
Regulatory status
Anktiva (nogapendekin alfa inbakicept-pmln, N-803) is an IL-15 receptor superagonist. Per its label it drives proliferation and activation of NK cells, CD8+ T cells and memory T cells without expanding regulatory T cells (approved label). Phase 1 data in solid tumors showed NK-cell expansion and early CD8 T-cell activation, but only modest changes in circulating CD8 counts and no objective tumor responses (Margolin et al., CCR 2018).
| Status | Indication | Basis |
|---|---|---|
| Approved | BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with BCG, intravesical. April 22, 2024. | 77 patients; CR 62% (95% CI 51–73); 58% of responses ≥12 months, 40% ≥24 months (FDA). Peer-reviewed cohort: CR 71%, median duration 26.6 months (Chamie et al., NEJM Evidence 2023). |
| Approved | Previously, the approved indication required carcinoma in situ (CIS), with or without papillary tumors; the expanded indication also includes high-grade papillary-only disease without CIS. | The FDA considered the previously demonstrated effectiveness of Anktiva plus BCG in patients with CIS alongside clinical and laboratory evidence showing important similarities between CIS and high-grade papillary tumors. These similarities supported applying the earlier efficacy evidence to high-grade papillary-only disease. (FDA approval details) Read the full update |
| Held up in FDA trials, unnecessarily | Lymphopenia reversal in relapsed/refractory solid tumors (ALC <1,000/µL), subcutaneous. | RMAT designation; FDA Expanded Access authorization June 2025. Expanded access is not approval and does not establish efficacy (company release). |
| Held up in FDA trials, unnecessarily | Glioblastoma, NSCLC, pancreatic cancer, multiple myeloma, Long COVID. | Clinical trials only. Company-reported, non-randomized signals: pancreatic (QUILT-88) OS HR 0.46 in patients whose lymphopenia reversed, a responder analysis subject to immortal-time bias (ASCO 2025); recurrent GBM mean ALC 0.9 → ≥1.4 × 10³/µL within one cycle, p < 0.001 (QUILT-3.078). |
"The survival data for lymphopenia reversal are single-arm and company-reported."
Correct. They are hypothesis-generating, and the right response is a randomized trial with ALC recovery as a pre-specified endpoint, not a shrug. The prognostic literature above, by contrast, is independent, peer-reviewed and decades old.
"The FDA sent the sponsor a warning letter."
It did, on March 13, 2026, about promotional claims (FDA). The letter addresses misleading efficacy claims, omitted risk information and promotion beyond the approved indication and route. It does not withdraw the approved indication, and it is why this site cites the label and the literature rather than the advertising.
"Why should HHS care about one company's drug?"
It should not, and this site does not ask it to. The ALC is already on every cancer patient's CBC. Whether the intervention is Anktiva, another IL-15 agonist, or spleen-sparing radiotherapy planning, the policy question is the same: why is a validated predictor of survival not monitored, reported, or acted on?
The ask
1 · Measure
Ask NCI and CDC to convene NCCN and ASCO to add ALC monitoring, with a threshold for action, to supportive-care and survivorship guidance, alongside the existing neutropenia guidance (NCCN). The number is already on the panel; the cost of the ask is a paragraph.
2 · Expedite
Welcome the expanded bladder-cancer approval and encourage appropriate expedited pathways when supported by evidence. Clarify the evidence needed for investigational uses; the papillary-only population is now included. (FDA approval details)
3 · Cover
Medicare can cover a therapy on condition that patients are enrolled in a registry or study, under Coverage with Evidence Development (CMS). Ask CMS to open a national coverage determination with CED for IL-15 therapy in treatment-related lymphopenia, tied to the existing expanded-access protocol. A registry could provide observational evidence; randomized studies would still be needed to establish treatment benefit.
And meet them. Justin, Lisa, Valerie, Andrew, Alan and Beth are alive and willing to sit across a table. Thirty minutes with them will do more than any deck.
For the clinic, today
We review figures against their cited sources, but this site is not a substitute for independent clinical review. If you find an error, or a guideline we missed, write to us and we will fix it and say so.